AD
Profound Medical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TULSA-PRO® | Localized Prostate Cancer (Primary Whole-Gland) | Commercial |
| Sonalleve® MR-HIFU | Uterine Fibroids | Commercial |
Leadership Team at Profound Medical
AM
Arun Menawat
Chief Executive Officer and Chairman of the Board
PD
Prof. Dr. Klaus Racké
Chairman of the Supervisory Board (Profound Medical GmbH)
RS
R. Scott King
Chief Financial Officer
PD
Prof. Dr. Stephan Rauschenberg
Member of the Supervisory Board
PD
Prof. Dr. Michael Friebe
Member of the Supervisory Board
DJ
Dr. John H. Reed
Chief Medical Officer
PD
Prof. Dr. Jürgen Jenne
Head of Research & Development
PD
Prof. Dr. Michael Moche
Medical Director